156 related articles for article (PubMed ID: 27184061)
1. Ultraviolet B irradiation in the prevention of alloimmunization in a dog platelet transfusion model.
Slichter SJ; Abrams K; Gettinger I; Christoffel T; Gaur L; Latchman Y; Nelson K; Pellham E; Bailey SL; Bolgiano D
Transfusion; 2016 Jun; 56(6):1340-7. PubMed ID: 27184061
[TBL] [Abstract][Full Text] [Related]
2. Evaluation of different methods of leukoreduction of donor platelets to prevent alloimmune platelet refractoriness and induce tolerance in a canine transfusion model.
Slichter SJ; Fish D; Abrams VK; Gaur L; Nelson K; Bolgiano D
Blood; 2005 Jan; 105(2):847-54. PubMed ID: 15231575
[TBL] [Abstract][Full Text] [Related]
3. Further studies to evaluate methods of leucoreduction to prevent alloimmune platelet refractoriness and induce tolerance in a dog platelet transfusion model.
Slichter SJ; Abrams K; Bailey SL; Pellham E; Gettinger I; Christoffel T; Gaur L; Latchman Y; Nelson K; Bolgiano D
Vox Sang; 2016 Jul; 111(1):62-70. PubMed ID: 27007858
[TBL] [Abstract][Full Text] [Related]
4. Reduced alloimmunization in mice following repeated transfusion with pathogen-reduced platelets.
Muench MO; Heitman JW; Inglis H; Fomin ME; Marschner S; Goodrich RP; Norris PJ; Jackman RP
Transfusion; 2016 Jun; 56(6):1419-29. PubMed ID: 27028210
[TBL] [Abstract][Full Text] [Related]
5. Leukofiltration plus pathogen reduction prevents alloimmune platelet refractoriness in a dog transfusion model.
Slichter SJ; Pellham E; Bailey SL; Christoffel T; Gettinger I; Gaur L; Latchman Y; Nelson K; Bolgiano D
Blood; 2017 Aug; 130(8):1052-1061. PubMed ID: 28705838
[TBL] [Abstract][Full Text] [Related]
6. Pathogen reduction with amotosalen/UVA reduces platelet refractoriness in a dog platelet transfusion model.
Slichter SJ; Bailey SL; Gettinger I; Pellham E; Christoffel T; Castro G; Green JM; Stassinopoulos A
Vox Sang; 2019 Aug; 114(6):595-604. PubMed ID: 31297836
[TBL] [Abstract][Full Text] [Related]
7. Evaluation of the tolerability and immunogenicity of ultraviolet C-irradiated autologous platelets in a dog model.
Pohler P; Lehmann J; Veneruso V; Tomm J; von Bergen M; Lambrecht B; Kohn B; Weingart C; Müller TH; Seltsam A
Transfusion; 2012 Nov; 52(11):2414-26. PubMed ID: 22404822
[TBL] [Abstract][Full Text] [Related]
8. Transfusion-induced alloimmunization and platelet refractoriness in a mouse model: mechanisms and interventions.
Waterman HR; Kapp LM; Munday A; Odem-Davis K; Zimring JC
Transfusion; 2016 Jan; 56(1):91-100. PubMed ID: 26400622
[TBL] [Abstract][Full Text] [Related]
9. Evidence-based platelet transfusion guidelines.
Slichter SJ
Hematology Am Soc Hematol Educ Program; 2007; ():172-8. PubMed ID: 18024626
[TBL] [Abstract][Full Text] [Related]
10. Longitudinal management with crossmatch-compatible platelets for refractory patients: alloimmunization, response to transfusion, and clinical outcomes (CME).
Wiita AP; Nambiar A
Transfusion; 2012 Oct; 52(10):2146-54. PubMed ID: 23113654
[TBL] [Abstract][Full Text] [Related]
11. Leukocyte reduction and ultraviolet B irradiation of platelets to prevent alloimmunization and refractoriness to platelet transfusions.
Trial to Reduce Alloimmunization to Platelets Study Group
N Engl J Med; 1997 Dec; 337(26):1861-9. PubMed ID: 9417523
[TBL] [Abstract][Full Text] [Related]
12. Prevention of platelet alloimmunization in dogs with systemic cyclosporine and by UV-irradiation or cyclosporine-loading of donor platelets.
Slichter SJ; Deeg HJ; Kennedy MS
Blood; 1987 Feb; 69(2):414-8. PubMed ID: 3801661
[TBL] [Abstract][Full Text] [Related]
13. Use and safety of riboflavin and UV light-treated platelet transfusions in children over a five-year period: focusing on neonates.
Jimenez-Marco T; Garcia-Recio M; Girona-Llobera E
Transfusion; 2019 Dec; 59(12):3580-3588. PubMed ID: 31587287
[TBL] [Abstract][Full Text] [Related]
14. Human Leukocyte Antigen Alloimmunization and Alloimmune Platelet Refractoriness.
Saris A; Pavenski K
Transfus Med Rev; 2020 Oct; 34(4):250-257. PubMed ID: 33127210
[TBL] [Abstract][Full Text] [Related]
15. HLA-universal platelet transfusions prevent platelet refractoriness in a mouse model.
Gras C; Schulze K; Goudeva L; Guzman CA; Blasczyk R; Figueiredo C
Hum Gene Ther; 2013 Dec; 24(12):1018-28. PubMed ID: 24090417
[TBL] [Abstract][Full Text] [Related]
16. CTLA4-Ig prevents alloantibody production and BMT rejection in response to platelet transfusions in mice.
Gilson CR; Patel SR; Zimring JC
Transfusion; 2012 Oct; 52(10):2209-19. PubMed ID: 22321003
[TBL] [Abstract][Full Text] [Related]
17. Ultraviolet B light-exposed human platelets mediate acute lung injury in a two-event mouse model of transfusion.
Gelderman MP; Chi X; Zhi L; Vostal JG
Transfusion; 2011 Nov; 51(11):2343-57. PubMed ID: 21492179
[TBL] [Abstract][Full Text] [Related]
18. HLA class I depletion by citric acid, and irradiation of apheresis platelets for transfusion of refractory patients.
Mirlashari MR; Vetlesen A; Nissen-Meyer LSH; Naper C; Tjønnfjord GE; Njerve IU; Ezligini F; Landmark BF; Meinke S; Sandgren P; Höglund P; Hetland G
Transfusion; 2021 Apr; 61(4):1222-1234. PubMed ID: 33580979
[TBL] [Abstract][Full Text] [Related]
19. Management of infants born with severe neonatal alloimmune thrombocytopenia: the role of platelet transfusions and intravenous immunoglobulin.
Bakchoul T; Bassler D; Heckmann M; Thiele T; Kiefel V; Gross I; Arnold DM; DiTomasso J; Smith JW; Paes B; Greinacher A
Transfusion; 2014 Mar; 54(3):640-5. PubMed ID: 23869512
[TBL] [Abstract][Full Text] [Related]
20. Platelet dose consistency and its effect on the number of platelet transfusions for support of thrombocytopenia: an analysis of the SPRINT trial of platelets photochemically treated with amotosalen HCl and ultraviolet A light.
Murphy S; Snyder E; Cable R; Slichter SJ; Strauss RG; McCullough J; Lin JS; Corash L; Conlan MG;
Transfusion; 2006 Jan; 46(1):24-33. PubMed ID: 16398727
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
